Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.36 |
| ▸ | GCG | P01275 | 8/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113000 | 0.88 | RCE1 (0.39) | RCE1PDE7AGCGHDAC6ABL1 | |
| SCHEMBL3102629 | 0.84 | GLP1R (0.39) | GCG | |
| SCHEMBL3104116 | 0.84 | GCG (0.49) | RCE1GCG | |
| SCHEMBL3099322 | 0.84 | RCE1 (0.53) | RCE1PDE7AHPGD | |
| SCHEMBL3102441 | 0.82 | RCE1 (0.36) | RCE1PDE7AGCGHDAC6ITGB3 | |
| SCHEMBL3095309 | 0.81 | RCE1 (0.35) | RCE1PDE7AGCGHDAC6ITGB3 | |
| SCHEMBL719577 | 0.80 | GCGR (0.37) | RCE1GCGHDAC6ABL1RIN1 | |
| SCHEMBL3095417 | 0.80 | NPC1 (0.40) | RCE1GCGHPGD | |
| SCHEMBL3110567 | 0.80 | RCE1 (0.35) | RCE1PDE7AGCGHDAC6ITGB3 | |
| SCHEMBL3099356 | 0.80 | RCE1 (0.35) | RCE1PDE7AGCGITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | RCE1 3126/4885PDE7A 3129/4885GCG 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.